打开APP

辉瑞收购Baxter两种脑膜炎疫苗产品或预示在该领域有所作为?

  1. Baxter
  2. 脑膜炎疫苗
  3. 辉瑞

来源:生物谷 2014-12-02 14:10

辉瑞收购Baxter两种脑膜炎疫苗产品或预示在该领域有所作为?

2014年12月2日讯 /生物谷BIOON/ --作为世界最为著名的生物医药巨头之一,辉瑞公司在今年的生物医药产业中频频成为瞩目的焦点。就在世界各方都在揣测辉瑞时候会卷土重来继续收购阿斯利康的时候,辉瑞公司已经不声不响的将Baxter公司的两种已上市疫苗产品NeisVac-C和FSME-IMMUN/TicoVac收入囊中。让人不得不感慨辉瑞在收购兼并方面经验之老辣。

而、根据辉瑞公司疫苗部门负责人表示,这一收购案也会进一步加强辉瑞疫苗部门在相关领域的实力。值得注意的是,此次收购的疫苗都是主要用于脑膜炎方面的疾病,而FSME-IMMUN/TicoVac则是Batxer公司于1976年上市的一种脑膜炎疫苗。不知这是否意味着今后辉瑞公司疫苗产业将在脑膜炎疾病疫苗领域将有大动作?而根据辉瑞公司12月1日透露的收购消息,公司还获得了Baxter公司位于奥地利的生产这两种疫苗的工厂。

NeisVac-C是一种专门预防由C型脑膜炎球菌(MenC)引起脑膜炎的疫苗。脑膜炎这种疾病会导致约15%的患者死亡,30%-50%的患者即使生存下来也会出现严重的肉体和精神方面的后遗症。MenC已经成为世界许多国家引起脑膜炎的主要病原体之一。而NeisVac-C已经被认为是预防由MenC引起的脑膜炎最为有效的疫苗之一。

而此次辉瑞公司收入囊中的另一个战利品FSME-IMMUN/TicoVac则是Baxter公司开发的专门用于预防蜱传脑炎的疫苗。蜱传脑炎主要是通过蜱虫叮咬传播蜱传脑炎病毒而引起的严重疾病。这一疾病多见于欧洲和亚洲地区。Baxter公司的FSME-IMMUN/TicoVac在1976年上市后已经获得了30多个国家和地区的准入批准,其接种量已经接近1亿2千万人次。(生物谷Bioon.com)

Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of Baxter International Inc.'s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. As previously announced, Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where these vaccines are manufactured.

"NeisVac-C and FSME-IMMUN/Ticovac are a strong fit with our vaccines business and this acquisition adds value, scale and depth to our existing portfolio of innovative vaccines,"said Susan Silbermann, president and general manager, Pfizer Vaccines."These best-in-class products enable us to reach a broader population with vaccines that prevent infections from serious and often fatal diseases."

About NeisVac-C and FSME-IMMUN/Ticovac

NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococci(MenC). This serious infection of the membrane covering the brain may be fatal in roughly 10-15 percent of patients1 and 30 percent to more than 50 percent of survivors may suffer from severe physical, social and mental damage2. MenC is one of the most prevalent meningococcal serogroups in many parts of the world and vaccination with NeisVac-C has been shown to be highly effective.

FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis (TBE), an infection of the brain, which is transmitted by the bite of ticks infected with the TBE-virus. Every year, the TBE virus causes thousands of cases of neuroinvasive illness in humans across Europe and Asia and is a growing public health concern in Europe and other parts of the world3. FSME-IMMUN/TicoVac is approved in 30 countries and has been marketed for over 30 years with approximately 120 million doses produced since 1976.

About Pfizer Inc.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

DISCLOSURE NOTICE

The information contained in this release is as of December 1, 2014. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer's acquisition of Baxter's portfolio of marketed vaccines and the potential benefits thereof, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the ability to realize the anticipated benefits of the acquisition; other business effects, including the effects of industry, economic, political or regulatory conditions; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information That May Affect Future Results", as well as in its subsequent reports on Form 10-Q and Form 8-K, all of which are filed with the Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->